Insight
Life Sciences Snapshot – Q3 2024 – A Quarterly Report on Financing Trends
October.07.2024
Navigating ARPA-H
Insight
Life Sciences Snapshot – Q2 2024 – A Quarterly Report on Financing Trends
June.26.2024
Novel Approaches to Treating Neurodegenerative Diseases
Insight
Deal Flow 4.0: 5 Things We Learned About European Tech Deal Terms in 2023
March.05.2024
Orrick’s Deal Flow 4.0 reveals European tech deal term trends from 350+ venture capital and growth equity investments our clients completed in 2023.
Insight
Life Sciences Snapshot – A Quarterly Report on Financing Trends – Q1 2024
February.26.2024
Women's & Reproductive Health
Insight
Tax-Exempt Bond Financing for Middle-Income Housing
January.09.2024
This booklet introduces the ways tax-exempt bonds can help produce rent- and income-restricted middle-income or “workforce” housing.
Insight
Life Sciences Snapshot – A Quarterly Report on Financing Trends – Q4 2023
November.10.2023
Leveraging Alternative Financing
Insight
Life Sciences Snapshot – A Quarterly Report on Financing Trends – Q3 2023
July.25.2023
Venture Funding and Tech Trends in AI in Drug Discovery
Insight
Life Sciences Snapshot – A Quarterly Report on Financing Trends – Q2 2023
April.25.2023
This edition of Orrick’s life sciences publication series reviews key trends of venture investment in the life sciences industry during Q1 2023.
Insight
Life Sciences Snapshot – A Quarterly Report on Financing Trends – Q1 2023
February.14.2023
Venture Funding and Tech Trends in Mental Health
Insight
Orrick Global Offshore Wind Report
by Minako Wakabayashi, Evan Stergoulis, Paul Zarnowiecki, Adam Smith and Oliver Sikora | December.12.2022
Powering Forward: Offshore Wind Growth Signals Things to Come
Insight
Life Sciences Snapshot – A Quarterly Report on Financing Trends – Q4 2022
October.24.2022
Leveraging Non-Dilutive Financing For Drug Development and Favorably Licensing Developed Products as a Global Health Model
Insight
Life Sciences Snapshot – A Quarterly Report on Financing Trends – Q3 2022
July.27.2022
Evolving Antitrust Scrutiny of Life Sciences M&A—What's in the Pipeline?